OR WAIT null SECS
Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.
Virk will chair a discussion on depression treatments on March 3.
Solving treatment-resistant depression has proven costly and challenging.
With many patients not responding to first, second, or third options of antidepressants, it is crucial to overcome this resistance barrier.
However, new treatments may soon emerge that has clinicians and investigators hopeful they will soon be able to overcome this long-standing challenge.
In an interview with HCPLive®, Subhdeep Virk, MBBS, an associate professor of clinical psychiatry and director of the Treatment Resistant Depression Program at Ohio State University’s Wexner Medical Department of Psychiatry, talked about the emergence of new therapies for depression and how there is hope on the horizon in treating this patient population
Virk will be chairing a discussion on treatment-resistant depression on March 3 as part of HCPLive’s State of the Science program called Institutional Perspectives in Psychiatry: Addressing Challenges in Depression Treatment.
The discussion will look at newer treatment options and why there is a need for novel, evidence-based treatments for depression.
“There are a lot of newer treatments for depression,” Virk said. “What my focus will be on is ketamine and esketamine. Those are the 2 treatments that have been more recently added to the group of treatments for treatment-resistant depression.”